Fuad El-Hibri Sells 40,000 Shares of Emergent Biosolutions, Inc. (EBS) Stock

Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total transaction of $1,614,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Friday, September 29th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $40.50, for a total transaction of $1,012,500.00.
  • On Wednesday, September 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $39.50, for a total transaction of $987,500.00.
  • On Thursday, September 14th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $38.50, for a total transaction of $962,500.00.
  • On Thursday, September 7th, Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total transaction of $616,462.50.
  • On Tuesday, September 5th, Fuad El-Hibri sold 3,100 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total transaction of $116,250.00.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total transaction of $204,787.50.

Emergent Biosolutions, Inc. (NYSE:EBS) traded down $0.43 on Wednesday, reaching $40.44. 256,300 shares of the company’s stock were exchanged, compared to its average volume of 323,975. Emergent Biosolutions, Inc. has a 52-week low of $25.96 and a 52-week high of $44.86. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38. The company has a market cap of $1,691.83, a price-to-earnings ratio of 21.62, a price-to-earnings-growth ratio of 1.13 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The firm had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same period in the previous year, the firm posted $0.56 EPS. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. research analysts expect that Emergent Biosolutions, Inc. will post 1.64 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.truebluetribune.com/2017/11/15/fuad-el-hibri-sells-40000-shares-of-emergent-biosolutions-inc-ebs-stock.html.

A number of institutional investors and hedge funds have recently bought and sold shares of EBS. Northern Trust Corp grew its holdings in Emergent Biosolutions by 47.2% during the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after acquiring an additional 290,863 shares during the last quarter. Vanguard Group Inc. grew its holdings in Emergent Biosolutions by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after acquiring an additional 238,194 shares during the last quarter. State Street Corp boosted its stake in shares of Emergent Biosolutions by 17.2% in the 1st quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after purchasing an additional 213,500 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after purchasing an additional 152,029 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of Emergent Biosolutions by 26.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 669,617 shares of the biopharmaceutical company’s stock valued at $22,707,000 after purchasing an additional 138,611 shares during the last quarter. 85.97% of the stock is currently owned by hedge funds and other institutional investors.

EBS has been the topic of several research reports. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Wednesday, October 25th. BidaskClub lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $45.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply